Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00884234 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
A Phase 2 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00884234 is a Phase 2 study that has completed, run by Revance Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT00884234, a Phase 2 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of 2 sequential doses of RT001 compared to vehicle control following applications at Baseline (Day 0) and Week 2.
Interventions
- OTHER Vehicle Control
- DRUG RT001 (Botulinum Toxin Type A Topical Gel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00884234
The ClinicalTrials.gov registry entry for NCT00884234 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Control is the first listed.
NCT00884234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00884234 about?
NCT00884234 is a clinical study titled "Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines". The purpose of this study is to determine the safety and efficacy of 2 sequential doses of RT001 compared to vehicle control following applications at Baseline (Day 0) and Week 2.
What is the current status of trial NCT00884234?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2009-02. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00884234?
The interventions under investigation include: Vehicle Control (OTHER), RT001 (Botulinum Toxin Type A Topical Gel) (DRUG).
Who is sponsoring clinical trial NCT00884234?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.